See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter ↵ to review claims
Explore by Goal
"The goal of science is not to open the door to infinite wisdom, but to set a limit to infinite error."
Field & focus: translational cancer immunology / tumor myeloid biology (MDSCs, TME, immunotherapy) supported by multiple high-impact papers
Long Explanation
Author Review — Patricia A. Rayman (visual first)
Quick visual summary
Productive, well-cited translational immunology researcher focused on myeloid-derived suppressor cells (MDSC), tumor microenvironment modulation, and immunotherapy — multiple papers in Clinical Cancer Research, Cancer Research, Neuro‑Oncology, and related journals.
Data source: OpenAlex author counts_by_year (processed into yearly cited_by counts) showing citation peaks around 2008–2010 and a strong peak in 2016 (reflecting high-impact translational immunology work)
Consistent translational focus: multiple clinical–translational studies link patient sample immunophenotyping (MDSC, Treg, neutrophils) to drug effects and outcomes — strengthens real-world relevance and translational impact ().
High-citation flagship papers: several papers (>300 citations each) published in respected journals (Clinical Cancer Research, Cancer Research, Neuro‑Oncology) indicate influence on tumor immunology and MDSC literature ().
Collaborative network & multi-disciplinary work: co-authorship with clinical oncologists and immunologists (e.g., Brian Rini, James Finke) signals translational collaborations linking bench and bedside (OpenAlex author lists and author positions support this).
Limitations, blind spots, and potential biases
Authorship position: many high-citation papers list Rayman as middle author rather than first/last — indicates strong collaborative contribution but fewer lead-author monographs; cannot from metadata alone infer the precise intellectual leadership per paper (OpenAlex author positions vary)
Field-wide confounders: translational immunology correlative studies (flow cytometry in patient samples) are sensitive to gating strategies, antibody panels, and cohort heterogeneity — replicability depends on methods details often in supplementary materials (check each paper for gating/controls). Example: MDSC phenotyping lacks universal standardization, a known community limitation (discussed in Cancer Res and CCR papers).
Potential citation/positive-result bias: high citations can reflect novelty or influential hypothesis generation but do not guarantee reproducibility across centers; some mechanistic claims are supported by both preclinical and clinical correlative data in this body of work, which improves robustness but still requires careful replication.
Concrete, evidence-based recommendations for interpreting Rayman’s output
When using her translational conclusions (e.g., sunitinib effects on MDSCs), cross-check the original methods & cohorts (sample sizes, gating, patient characteristics) because correlative immunology is cohort-sensitive ().
For meta-analyses or reviews, preferentially weight her papers that combine clinical samples with mechanistic validation (preclinical + patient data) because these are more robust to over-interpretation than single-arm preclinical reports.
Patricia A. Rayman is a productive, mid-career to senior translational immunology author whose work is influential in tumor myeloid biology (MDSC) and immunotherapy correlative science. The strongest evidence for scientific impact lies in multiple well-cited clinical/translational papers published in respected oncology journals that combine patient cohorts with immunophenotyping and mechanistic follow-up, increasing confidence that findings influenced the field. Caveats include variable authorship position (many collaborative middle-author roles), the inherent limits of correlative immunology, and the need to inspect individual methods for reproducibility-sensitive details (flow-cytometry panels, gating, cohort composition). Confidence in these assessments is moderate-to-high because of high citation counts and repeated, converging lines of translational evidence in multiple tumor types ().
Actionable next steps
For reproducibility: obtain raw flow-cytometry gating files (FCS) from key papers or authors when possible to re-analyze MDSC phenotypes across cohorts.
For meta-analytic synthesis: pool only studies with standardized MDSC definitions and include study-level covariates (tumor type, therapy, sample timing) to avoid heterogeneity-driven artifacts.
If you want a deeper, automated meta-analysis of Rayman's MDSC-related papers (extract effect sizes, methods heterogeneity, and produce forest plots), you can run an AI Science Agent to fetch and re-analyze raw supplementary data across the cited papers.
Key source material used to construct this review: OpenAlex author profile counts_by_year and top works; Clinical Cancer Research and Cancer Research primary papers cited above for direct evidence of translational findings and citation impact.
Feedback:
Updated: March 17, 2026
BGPT Author Review
Scientific Quality
80%
Rayman's publication record shows sustained, high-impact translational contributions (h~40–41; multiple >300-citation papers) focused on tumor myeloid biology and immunotherapy; strengths: translational clinical–mechanistic linkage, reproducible influence across tumor types; weaknesses: frequent middle-author positions (collaborative role), dependence on correlative assays whose reproducibility depends on methodological details, and limited number of sole-first/last-author flagship conceptual papers.
Communication Quality
70%
Papers are published in well-edited oncology/immunology journals and present clear translational narratives and correlative data; communication is effective for expert audiences, though some method details (e.g., flow-cytometry gating) require careful reading in supplements and may limit accessibility to non-specialists.
Author Novelty
70%
Work advanced novel translational links between targeted therapy (sunitinib) and immune microenvironment modulation, and applied these ideas across tumor types; novelty is high within translational MDSC literature but builds on emerging community concepts rather than introducing wholly unprecedented paradigms.
Scientific Rigor
70%
Multiple clinical/translational papers combine patient cohorts and mechanistic follow-up, which increases rigor; however, correlative designs and variable authorship roles mean some claims rely on cohort-specific assays and require independent replication and careful methodological scrutiny.
Fetching full-texts and extracting per-paper citation counts, cohort sizes, and method keywords (flow cytometry gating) to produce meta-analytic tables and forest plots from Rayman's MDSC-related papers.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
Hypothesis: MDSC counts alone predict immunotherapy response across cancer types — falsified because tumor-specific microenvironments and chemokine milieus modulate MDSC function and trafficking, so counts alone lack generalizable predictive power.
Hypothesis: All RTK inhibitors uniformly reduce MDSCs — falsified because class- and drug-specific effects are compartmental and depend on off-target profiles (sunitinib shows specific effects not shared by all RTKis).
Quick Explanation
Long Explanation
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
Keep Exploring
